- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00604422
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis
Přehled studie
Postavení
Detailní popis
Ulcerative colitis (UC) is a disorder of unknown origin that may be characterized by acute and chronic inflammation of the colon. The extent of the colonic mucosal inflammation varies among individuals, but the disease almost always involves the rectum. Ulcerative colitis has required evaluation by colonoscopy to determine the extent and severity of the disease. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon.
The PillCam® SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 700,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. Further details of the PillCam® Colon Capsule Endoscope (PCCE) can be found in the device description section.
In previous studies, the PillCam colon platform has been shown to be safe and to be able to demonstrate colon polyps and cancers. This study is an extension to a trial evaluating the use of PCCE in ulcerative colitis that has already been completed in Hong Kong (n=40). This study is designed to assess the ability of the capsule to accurately detect inflammatory lesions and thus classifying the extent and severity of disease in subjects with ulcerative colitis in comparison to traditional colonoscopy.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Hong Kong, Hongkong
- Chinese university of Hong Kong, Princes of Walses Hospital
-
-
-
-
-
Singapore, Singapur, 119074
- Department of Medicine, National University Hospital
-
-
-
-
-
Taipei, Tchaj-wan
- Department of Internal Medicine & Health Management Center, National Taiwan University Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.
Popis
Inclusion Criteria:
- Subjects 18-70
- Suspected or known ulcerative colitis patients
Exclusion Criteria:
- Subject has dysphagia
- Subject has congestive heart failure
- Subject who can not tolerate bowel preparation
- Poor bowel preparation
- Subject has renal insufficiency
- Subject is known or is suspected to suffer from intestinal obstruction.
- Subject has a cardiac pacemaker or other implanted electro-medical devices.
- Subject is pregnant
- Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
- Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
- Subject has any condition, which precludes compliance with study and/or device instructions.
- Subject suffers from life threatening conditions
- Subject is currently participating in another clinical study
- Subject has constipation (less than 3 bowel movements/week)
- Subject has known slow gastric emptying time
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
A
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Agreement level between capsule and colonoscopy in classifying colitis into the above (see section 3.1) categories.
Časové okno: within 7 days
|
within 7 days
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Number, type and severity of adverse events with both PCCE and standard colonoscopy
Časové okno: Within 7 days
|
Within 7 days
|
|
Accuracy parameters for detecting active UC
Časové okno: within 7 days
|
within 7 days
|
|
Disease severity scoring index for both PCCE and .standard colonoscopy
Časové okno: within 7 days
|
within 7 days
|
|
Colon cleansing level score for both PCCE and standard colonoscopy.
Časové okno: within 7 days
|
within 7 days
|
|
Grading of the bubbles interference at the colon for PCCE.
Časové okno: Within 7 days
|
Within 7 days
|
|
Percentage of excreted colon capsules
Časové okno: Within 7 Days
|
Within 7 Days
|
|
PCCE transit time from ingestion to excretion and colon transit time
Časové okno: Within 7 Days
|
Within 7 Days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Josef Sung, Prof., Chinese University of Hong Kong
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- MA-107
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .